Description
Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia are highly prevalent gastrointestinal disorders worldwide. These conditions often coexist, making clinical differentiation difficult.
- The global prevalence of GERD is around 99%, and Functional Dyspepsia affects 20–30% of the general population.
- Proton Pump Inhibitors (PPIs), alone or combined with prokinetic agents, are proven effective in relieving symptoms and improving quality of life in acid-related disorders.
ESOBRICK-L
Composition: Esomeprazole EC 40 mg + Levosulpiride SR 75 mg Capsule
Indications
- GERD (Gastroesophageal Reflux Disease)
- NAB (Nocturnal Acid Breakthrough)
- Diabetic Gastroparesis
- Functional Dyspepsia
- Gastritis
- Acid Peptic Disorders
Mechanism of Action
Esomeprazole:
A selective proton pump inhibitor (PPI) that blocks the H⁺/K⁺ ATPase enzyme in gastric parietal cells, leading to effective suppression of gastric acid secretion.
Levosulpiride:
A prokinetic and anti-dyspeptic agent acting as a D₂ receptor antagonist and 5-HT₄ receptor agonist. It has better tolerability than cisapride and metoclopramide and is free of serious cardiovascular side effects.
Key Features
- Rapid pH Control: Esomeprazole maintains intragastric pH >4 longer than other PPIs.
- Safe Prokinetic Options: Domperidone and Levosulpiride avoid significant CNS or cardiovascular effects.
- Dual Action: Combination therapy provides both acid suppression and motility enhancement.
Dosage
ESOBRICK L:
Once daily or as directed by a registered medical practitioner.
Presentation
- ESOBRICK L: Alu-Alu Strip of 10 capsules
Reviews
There are no reviews yet.